- FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC.
- Harris J.
- OncLive. 2022 Dec 15.
- News
- Free Full Text
•• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Dec 15.)
- Molecular profiling of male breast cancer by multigene panel testing: implications for precision oncology.
- Valentini V, Silvestri V, Bucalo A, Conti G, Karimi M, Di Francesco L, Pomati G, Mezi S, Cerbelli B, Pignataro MG, Nicolussi A, Coppa A, D'Amati G, Giannini G, Ottini L.
- Front Oncol. 2022 Dec 12;12:1092201. doi: 10.3389/fonc.2022.1092201.
- Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis.
- Fazekas T, Széles ÁD, Teutsch B, Csizmarik A, Vékony B, Váradi A, Kói T, Lang Z, Ács N, Kopa Z, Hegyi P, Hadaschik B, Grünwald V, Nyirády P, Szarvas T.
- Prostate Cancer Prostatic Dis. 2022 Dec 12. doi: 10.1038/s41391-022-00626-2. Epub ahead of print.
- PMID: 36509931
- PubMed abstract
- Meta-Analysis
- Free Full Text